Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ficerafusp Alfa + Nivolumab in Platinum Refractory HNSCC
NCT07529873Phase 2Recruiting
- Sponsor
- GORTEC
- Start
- Mar 2026
- Primary completion
- Apr 2030
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ficerafusp alfa in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Started Mar 2026; status: recruiting.
02
Drugs
ficerafusp alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07529873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07529873.